期刊文献+

抑制血管生成治疗骨肉瘤的研究进展 被引量:2

下载PDF
导出
摘要 骨肉瘤是最常见的原发性骨恶性肿瘤,血运丰富,发展迅速,可早期通过血行转移,尤其是肺转移,给治疗带来极大困难。骨肉瘤的生长和转移均是血管生成依赖性的,抑制骨肉瘤的血管生成从而阻断骨肉瘤的营养供给和转移途径可望成为治疗骨肉瘤的新策略,而且骨肉瘤作为血管极其丰富的恶性实体肿瘤,是研究肿瘤抗血管治疗的理想模型。现就近年来抑制血管生成治疗骨肉瘤的研究进展作一综述。
出处 《中国骨肿瘤骨病》 CAS 2007年第6期370-374,共5页 Chinse Journal Of Bone Tumor And Bone Disease
基金 福建医科大学教授基金项目(编号TS06031) 福建省卫生厅青年科研基金
  • 相关文献

参考文献31

  • 1[1]Tsunemi T,Nagoya S,Kaya M,et al.Postopreative progression of pulmonary metastasis in osteosarcoma.Clin Orthop Relat Res,2003,407:159-166.
  • 2[3]Semenza GL.Targeting HIF-1 for cancer therapy.Nat Rev Cancer,2003,3:721-732.
  • 3[4]Mabjeesh NJ,Escuin D,LaVallee TM,et al.2ME2 inhibits tumor growth and angiogenesis by disrupting Microtubules and dysregulating HIF.Cancer Cell,2003,3:363-375.
  • 4[5]Noan M,Chau PR,Wynne A.Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-l activity and hypoxia-inducible factor-lα induction in response to hypoxic stress and growth factors.Cancer Res,2005,65:4918-4928.
  • 5吴强,杨述华,叶树楠,王锐英.RNA干扰沉默缺氧诱导因子-1α治疗骨肉瘤的实验研究[J].中华医学杂志,2005,85(6):409-413. 被引量:19
  • 6[7]Takayama K,Ueno H,Nakanishi Y.Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.Cancer Res,2000,77:2169-2177.
  • 7[8]Charity RM,Foukas AF,Deshmukh NS,et al.Vascular endothelial growth factor expression in osteosarcoma.Clin Orthop Relat Res,2006,448:193-198.
  • 8[9]Oda Y,Yamamoto H,Tamiya S,et al.CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma:analysis within a group of patients,all of whom developed lung metastasis.Mod Pathol,2006,19:738-745.
  • 9王燕,汪睿,乔慧,李晋云,彭挺生,李扬,张萌,梁惠珍,丘钜世.缺氧反应元件启动子表达反义血管内皮生长因子(VEGF)_(165)cDNA靶向性抑制骨肉瘤细胞VEGF表达[J].中华病理学杂志,2005,34(9):588-591. 被引量:6
  • 10[12]Falareau P,Champagne P,Poyet P,et al.Neovastat:a naturally occurring multifunctional antiangiogenic drug,in phase 3 clinical trials.Semin Oncol,2001,28:6.

二级参考文献45

  • 1沈先荣,贾福星.血管生成抑制因子在肿瘤防治中的研究进展[J].国外医学(药学分册),1994,21(4):215-220. 被引量:16
  • 2贾福星,沈先荣,王玲,雷呈祥.软骨抗癌活性成分抑制血管生成机理的研究[J].中国生化药物杂志,1997,18(2):68-71. 被引量:6
  • 3王贵齐,王耐勤,刘彤,徐光炜,董志伟.血管内皮生长因子抗体对实验性肿瘤的抑制作用[J].中华肿瘤杂志,1997,19(3):163-166. 被引量:18
  • 4Krishnamachary B,Berg-Dixon S,Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res,2003,63:1138-1143.
  • 5Kaelin WG Jr. How oxygen makes its presence felt. Genes Dev,2002,16:1441-1445.
  • 6Wang GL,Semenza GL.Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem,1993,268:21513-21518.
  • 7Zhong H, De Marzo AM, Laughner E,et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res,1999,59: 5830-5835.
  • 8Dai S, Huang ML, Hsu CY, et al. Inhibition of hypoxia inducible factor 1α causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys,2003,55:1027-1036.
  • 9Sun X, Kanwar JR, Leung E, et al. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther,2001,8: 638-645.
  • 10Teicher BA. Hypoxia and drug resistance. Cancer Metas Rev, 1994,13:139-168.

共引文献36

同被引文献15

  • 1沙丹,何友兼.VEGF及其受体Flt-1、KDR在鼻咽癌组织中的表达及意义[J].癌症,2006,25(2):229-234. 被引量:21
  • 2Grewe M,Gansauge F,Schmid RM,et al.Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells.Cancer Res,1999,59:3581-3587.
  • 3Mita MM,Mira A,Rowinsky EK.Mammalian target of rapamycin:a new molecular target for breast cancer.Clin Breast Cancer,2003.4:126-137.
  • 4Semela D,Piguet AC,Kolev M,et al.Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.J Hepatol,2007,46:840-848.
  • 5Yanai Y,Micallef MJ,Yamamoto S,et al.Expression profiling of tumor necrosis factor alpha-induced apoptosis-associated genes in human solid tumor cell lines.Anticancer Res,2003,23:2339-2348.
  • 6Ory B,Moriceau G,Redini F,et al.mTOR inhibitors (rapamycin and its derivatives)and nitrogen containing bisphosphonates:bi-functional compounds for the treatment of bone tumours.Curr Med Chem,2007,14:1381-1387.
  • 7Albers M W,Williams RT,Brown EJ,et al.FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line.J Biol Chem,1993,268:22825-22829.
  • 8Gazitt Y,Kolaparthi V,Moncada K,et al.Targeted therapy of human osteosarcoma with 17AAG or rapamycin:Characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.Int J Oncol,2009,34:551-561.
  • 9Guba M,von Breitenbuch P,Steinbauer M,et al.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor.Nat Med,2002,8:128-135.
  • 10Joo HJ,Oh DK,Kim YS,et al.Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma[J].BJU Int,2004,93(3):291-296.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部